Document is current
Any future updates will be listed below
-
Authors
Tseng, William W.
Barretta, Francesco
Fiore, Marco
Radaelli, Stefano
Baia, Marco
Borghi, Alessandra
Colombo, Chiara
Sanfilippo, Roberta
Fabbroni, Chiara
Stacchiotti, Silvia
Di Blasi, Elena
Sangalli, Claudia
Allajbej, Albina
Morosi, Carlo
Vanzulli, Andrea
Pasquali, Sandro
Callegaro, Dario
Gronchi, Alessandro
-
Funding
Funding for this research was provided by:
City of Hope
- License Information
-
More Information
Article History
Received: 6 February 2026
Accepted: 17 April 2026
First Online: 5 May 2026
Change Date: 16 May 2026
Change Type: Update
Change Details: An additional affiliation was added for Roberta Sanfilippo.
Disclosure
: Silvia Stacchiotti has personal financial interests (honoraria, consultancy or advisory role) in Bayer, Boehringer, Daiichi Sankyo, Deciphera, Gentili, Glaxo Smith Kline, Ikena, Ipsen, Merk Serono, NEC Oncoimmunity, Novartis, Orion, Parabilis, Peerview, Pharmamar, Pharma Essentia, Servier, and Sun Pharmaceuticals, as well as institutional financial interests (funding to her institution for clinical studies in which she is the principal investigator) in Abbisko, Advenchen, Daiichi Sankyo, Deciphera, Eisai, Epizyme, Foghorn, Glaxo Smith Kline, Inhibrix, Ipsen, Merck Serono, Pharmamar, Springworks.
